Divi's Laboratories Limited has informed the Exchange about Transcript
DIVISLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Divi's Laboratories reported Q1 FY26 consolidated total income of ₹2,529 crores, up 15% year-on-year from ₹2,197 crores, with profit after tax rising 27% to ₹545 crores from ₹430 crores. Constant currency growth for the quarter was 14%, capacity utilization held at 80%, and the nutraceutical business grew around 40% to ₹250 crores. Management raised the FY26 capital expenditure guidance to ₹2,000 crores (from ₹1,400 crores earlier), driven by three new custom synthesis projects that are backed by long-term supply commitments. Generic pricing pressure continues, though management expressed hope for stabilization in coming quarters, and new generic launches like Brivaracetam and Ticagrelor are expected to move to commercial volumes in 6–12 months. Unit 3 Kakinada, operational since January 2025, is supporting backward integration and freeing up GMP capacity at Units 1 and 2 for new molecules.
The strong earnings growth and higher capex guidance point to management confidence in visible custom synthesis demand, particularly from peptides/GLP-1 opportunities. However, persistent generic pricing pressure remains a margin headwind, and the company's heavy reliance on confidentiality-related disclosures (CDAs) limits investor visibility into product-level concentration and the actual scale of new contract ramp-ups.